Davis MP - Search Results

1

Phase II evaluation of piroxantrone in renal cell carcinoma. A Southwest Oncology Group Study.

Allen A, Wolf M, Crawford ED, Davis MP, Natale RB, Barnett ML. Allen A, et al. Among authors: davis mp. Invest New Drugs. 1992 Jul;10(2):129-32. doi: 10.1007/BF00873131. Invest New Drugs. 1992. PMID: 1500267 Free article. Clinical Trial.

2

Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study.

Balducci L, Blumenstein B, Von Hoff DD, Davis M, Hynes HE, Bukowski RM, Crawford ED. Balducci L, et al. Cancer Treat Rep. 1987 May;71(5):543-4. Cancer Treat Rep. 1987. PMID: 2436773 No abstract available.

3

High versus low-dose cisplatin combined with vinblastine and bleomycin and selective surgical resection of residual disease in patients with disseminated testicular cancer: a Southwest Oncology Group Study.

Crawford ED, Samson M, Klugo RC, Dawkins CA, Davis M. Crawford ED, et al. Prog Clin Biol Res. 1985;203:363-80. Prog Clin Biol Res. 1985. PMID: 2421331 No abstract available.

4

Adverse reactions to the intravesical administration of doxorubicin hydrochloride: report of 6 cases.

Crawford ED, McKenzie D, Mansson W, Totonchy M, Grossman HB, Davis M, Lamm DL, Duchek M. Crawford ED, et al. J Urol. 1986 Sep;136(3):668-9. doi: 10.1016/s0022-5347(17)45010-5. J Urol. 1986. PMID: 3735544

5

Are Muscle and Fat Loss Predictive of Clinical Events in Pancreatic Cancer? The Importance of Precision Metrics.

Davis MP, Bader N, Basting J, Vanenkevort E, Koppenhaver N, Patel A, Gupta M, Lagerman B, Wojtowicz M. Davis MP, et al. J Pain Symptom Manage. 2024 Oct 24:S0885-3924(24)01054-6. doi: 10.1016/j.jpainsymman.2024.10.004. Online ahead of print. J Pain Symptom Manage. 2024. PMID: 39461674

6

The Surprise Question: Not Ready for Prime Time.

Davis MP. Davis MP. Palliat Med Rep. 2024 Oct 9;5(1):438-439. doi: 10.1089/pmr.2024.0071. eCollection 2024. Palliat Med Rep. 2024. PMID: 39440110 No abstract available.

7

Respiratory Depression Associated with Opioids: A Narrative Review.

Davis MP, DiScala S, Davis A. Davis MP, et al. Curr Treat Options Oncol. 2024 Nov;25(11):1438-1450. doi: 10.1007/s11864-024-01274-5. Epub 2024 Oct 21. Curr Treat Options Oncol. 2024. PMID: 39432171 Review.

8

Advancing immunomodulatory functions in mesenchymal stem/stromal cells through targeting the GATA6-mediated pathway.

Lin EC, Davis MP, Lee MS, Ma G, Xu W, Chang YI, Li WJ. Lin EC, et al. Among authors: davis mp. Cytotherapy. 2025 Jan;27(1):85-97. doi: 10.1016/j.jcyt.2024.08.001. Epub 2024 Aug 8. Cytotherapy. 2025. PMID: 39207345

9

Correction to: Opioid analgesic dose and route conversion ratio studies: a scoping review to inform an eDelphi guideline.

Davis MP, Davies A, McPherson ML, Reddy A, Paice JA, Roeland E, Walsh D, Mercadante S, Case A, Arnold R, Satomi E, Crawford G, Bruera E, Ripamonti C. Davis MP, et al. Support Care Cancer. 2024 Aug 20;32(9):596. doi: 10.1007/s00520-024-08820-9. Support Care Cancer. 2024. PMID: 39162866 No abstract available.

10

Novel drug treatments for pain in advanced cancer and serious illness: a focus on neuropathic pain and chemotherapy-induced peripheral neuropathy.

Davis MP. Davis MP. Palliat Care Soc Pract. 2024 Jul 31;18:26323524241266603. doi: 10.1177/26323524241266603. eCollection 2024. Palliat Care Soc Pract. 2024. PMID: 39086469 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

347 results

Search Page

Filters